A Phase III, Multicenter, Open-Label Long-Term Trial to Study the Efficacy and Safety of MK-4117 in Japanese Subjects With Eczema/Dermatitis and Dermal Pruritus
Latest Information Update: 05 May 2022
Price :
$35 *
At a glance
- Drugs Desloratadine (Primary)
- Indications Dermatitis; Eczema; Pruritus
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Merck Sharp & Dohme; Organon
- 03 Apr 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 03 Jan 2014 New trial record